iifl-logo

Dr Reddys Laboratories Ltd Shareholding & Investor Pattern

1,268.1
(1.21%)
Sep 5, 2025|03:31:04 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Dr Reddys Laboratories Ltd SHAREHOLDING

Jun-2025Mar-2025Dec-2024Sep-2024Jun-2024

Promoter

-

-

-

-

-

Foreign

0%

0%

0%

0%

0%

Indian

26.63%

26.64%

26.64%

26.64%

26.65%

Total Promoter

-

-

-

-

-

Institutions

63.09%

62.91%

62.98%

63.22%

62.99%

Non-Institutions

10%

10.15%

10.22%

9.97%

10.18%

Total Non-Promoter

73.09%

73.06%

73.2%

73.19%

73.17%

Custodian

0.26%

0.29%

0.15%

0.16%

0.17%

Total

100%

100%

100%

100%

100%

  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 26.63%

Non-Promoter- 63.09%

Institutions: 63.09%

Non-Institutions: 10.00%

Custodian: 0.26%

Dr Reddys Labs: Related NEWS

Dr Reddy’s Infuses ₹565 Cr into Russian Arm

The capital was infused via cash and will be used to support DRL Russia’s working capital requirements.

28 Jul 2025|12:22 PM
Read More
Dr Reddy’s Laboratories inks pact with Alvotech; stock gains ~3%

As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share costs and responsibilities.

5 Jun 2025|11:00 AM
Read More
Dr. Reddy’s Receives Two USFDA Observations for New York API Manufacturing Plant

Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.

18 May 2025|07:17 PM
Read More
Dr Reddy’s Q4 Profit Jumps 22% to ₹1,594 Crore

The board has recommended a final dividend of ₹8 per equity share for FY 2024–25

12 May 2025|01:00 PM
Read More
Top Stocks for Today - 12th May 2025

Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.

12 May 2025|09:32 AM
Read More
Dr. Reddy’s Laboratories Sells 14 ANDAs to Senores Pharma

Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.

5 Mar 2025|11:05 AM
Read More
Top Stocks for - 27th February 2025

Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.

26 Feb 2025|09:22 PM
Read More
Dr Reddy’s Hyderabad API Unit Gets USFDA VAI Classification

Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore. 

25 Feb 2025|08:42 PM
Read More
Dr Reddy’s Laboratories Q3 net profit zooms ~3%

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

24 Jan 2025|10:23 AM
Read More
Top Stocks for Today - 24th January 2025

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

24 Jan 2025|07:50 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.